Fewer anti-VEGF injections needed after treatment with ADVM-022 in wet AMD

Patients with neovascular age-related macular degeneration treated with ADVM-022 in the OPTIC phase 1 study have experienced a substantial reduction in annualized anti-VEGF injection frequency, according to a speaker.
“ADVM-022 is demonstrating a robust treatment response, long-term durability beyond 15 months from a single intravitreal injection and zero rescues in cohort 1, the high-dose cohort,” Carl D. Regillo, MD, FACS, said at the virtual American Academy of Ophthalmology annual meeting.
Regillo presented available data from the four cohorts in the OPTIC phase 1 study, a

Full Story →